U.S., May 3 -- ClinicalTrials.gov registry received information related to the study (NCT06954805) titled 'Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)' on April 24.
Brief Summary: The purpose of this study is to find out if there is a benefit to giving rituximab with etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (R-EPOCH) in participants who have high-risk B-cell PTLD in their 2nd phase of treatment (consolidation) while those with low-risk disease will be spared of chemotherapy and treated with rituximab consolidation alone.
This study is also being done to find out about the usefulness of circulating tumor DNA (ctDNA), a novel blood test which, has been shown to help guide treatmen...